The present disclosure relates to methods and intermediates useful for preparing a compound of formula I:

##STR00001##

or a co-crystal, solvate, salt or combination thereof.

Psilocin formulations of psilocin mucate with improved stability, physical properties and/or handling characteristics, as well as enhanced pharmacologic activity, pharmacokinetic parameters and safety characteristics as compared to psilocin or psilocybin and methods for their use are provided.

Processes are provided for the production of methenamine mandelate that do not require the isolation of produced methenamine prior to production of the methenamine mandelate.

Processes are provided for the production of methenamine mandelate that do not require the isolation of produced methenamine prior to production of the methenamine mandelate.

The present invention relates to the technical field of organic chemistry, specifically an asymmetrical hydrogenation of an -ketonic acid compound, the technical proposal being as shown by the following formula: ##STR00001## Wherein R.sup.1 is a phenyl, a substituted phenyl, a naphthyl a substituted naphthyl, a C.sub.1-C.sub.6 alkyl or aralkyl, the substitute is a C.sub.1-C.sub.6 alkyl, a C.sub.1-C.sub.6 alkoxy, a halogen, the number of the substituents is 1-3. M is a chiral spiro-pyridyl amido phosphine ligand iridium complex having the following structure, ##STR00002## Wherein, R is hydrogen, 3-methyl, 4-.sup.tBu or 6-methyl

The present invention relates to the technical field of organic chemistry, specifically an asymmetrical hydrogenation of an -ketonic acid compound, the technical proposal being as shown by the following formula: ##STR00001## Wherein R.sup.1 is a phenyl, a substituted phenyl, a naphthyl a substituted naphthyl, a C.sub.1-C.sub.6 alkyl or aralkyl, the substitute is a C.sub.1-C.sub.6 alkyl, a C.sub.1-C.sub.6 alkoxy, a halogen, the number of the substituents is 1-3. M is a chiral spiro-pyridyl amido phosphine ligand iridium complex having the following structure, ##STR00002## Wherein, R is hydrogen, 3-methyl, 4-.sup.tBu or 6-methyl

The present invention relates to a mandelate form of 1-(4-(((6-amino-5-(4-phenoxyphenyl) pyrimidin-4-yl)amino)methyl)piperidin-1-yl)prop-2-en-1-one (INN: evobrutinib) and a process of producing the same. Furthermore, the invention relates to a pharmaceutical composition comprising the mandelate form of evobrutinib and at least one pharmaceutically acceptable excipient. The pharmaceutical composition of the present invention can be used as a medicament, in particular for the treatment and/or prevention of multiple sclerosis.

The present invention relates to a mandelate form of 1-(4-(((6-amino-5-(4-phenoxyphenyl) pyrimidin-4-yl)amino)methyl)piperidin-1-yl)prop-2-en-1-one (INN: evobrutinib) and a process of producing the same. Furthermore, the invention relates to a pharmaceutical composition comprising the mandelate form of evobrutinib and at least one pharmaceutically acceptable excipient. The pharmaceutical composition of the present invention can be used as a medicament, in particular for the treatment and/or prevention of multiple sclerosis.

The present disclosure relates to methods and intermediates useful for preparing a compound of formula I: ##STR00001## or a co-crystal, solvate, salt or combination thereof.

The present disclosure relates to methods and intermediates useful for preparing a compound of formula I: ##STR00001## or a co-crystal, solvate, salt or combination thereof.